Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Clinical trial NCT06696183 · RECRUITING
Trial details
- NCT number
- NCT06696183
- Sponsor
- Technische Universität Dresden
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-25
- Primary completion
- 2029-04-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.